The CSF profile linked to cortical damage predicts Multiple Sclerosis activity.

OBJECTIVE Intrathecal inflammation correlates with the grey matter damage since the early stages of Multiple Sclerosis (MS), but whether the cerebrospinal fluid (CSF) profile can help to identify patients at risk of disease activity is still unclear. METHODS We evaluated the association between CSF levels of 18 cytokines, previously found to be associated to grey matter damage, and the disease activity, among 99 relapsing-remitting MS patients, who underwent blinded clinical and 3T-MRI evaluations for 4 years. Groups with (EDA) or without (NEDA) evidence of disease activity (occurrence of relapses, new white matter lesions, EDSS change) were identified. Cortical lesions and the annualized cortical thinning were also evaluated. RESULTS Fortyone patients experienced EDA and, compared to the NEDA group, had at diagnosis higher CSF levels of CXCL13, CXCL12, IFNγ, TNF, sCD163, LIGHT and APRIL (p<0.001). In the multivariate analysis, CXCL13 (HR=1.35, p=0.0002), LIGHT (HR=1.22, p=0.005) and APRIL (HR=1.78, p=0.0001) were the CSF molecules more strongly associated with the risk of EDA. The model including CSF variables predicted more accurately the occurrence of disease activity than the model with only clinical/MRI parameters (C-index at 4 years= 71% vs 44%). Finally, higher CSF levels of CXCL13 (β=4.7*10-4 ,p<0.001), TNF (β=3.1*10-3 ,p=0.004), LIGHT (β=2.6*10-4 ,p=0.003), sCD163 (β=4.3*10-3 ,p=0.009) and TWEAK (β=3.4*10-3 ,p=0.024) were associated with more severe cortical thinning. INTERPRETATION A specific CSF profile, mainly characterized by elevated levels of B-cell related cytokines, distinguishes patients at high risk of disease activity and severe cortical damage. The CSF analysis may allow stratifications of patients at diagnosis for optimizing therapeutic approaches. This article is protected by copyright. All rights reserved.

[1]  H. Lassmann Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis , 2019, Front. Immunol..

[2]  A. Oturai,et al.  Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis , 2018, Multiple sclerosis.

[3]  C. Gasperini,et al.  Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectives , 2018, Multiple Sclerosis and Demyelinating Disorders.

[4]  M. Bozzali,et al.  CSF β-amyloid predicts prognosis in patients with multiple sclerosis , 2018, Multiple sclerosis.

[5]  M. Filippi,et al.  MRI in multiple sclerosis: what is changing? , 2018, Current opinion in neurology.

[6]  M. Calabrese,et al.  The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis , 2018, Neurology.

[7]  F. Facchiano,et al.  Inflammatory intrathecal profiles and cortical damage in multiple sclerosis , 2018, Annals of neurology.

[8]  A. B. Lyons,et al.  Absence of Tumor Necrosis Factor Supports Alternative Activation of Macrophages in the Liver after Infection with Leishmania major , 2018, Front. Immunol..

[9]  M. Calabrese,et al.  Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study , 2017, Multiple sclerosis.

[10]  E. Havrdová,et al.  “No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis , 2017, Multiple sclerosis.

[11]  F. Berven,et al.  Label‐free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis , 2016, Proteomics.

[12]  P. Williamson,et al.  Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis , 2015, Annals of neurology.

[13]  P. Nichelli,et al.  Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis , 2015, Journal of Neuroimmunology.

[14]  H. Møller,et al.  Biomarkers of Inflammation and Axonal Degeneration/Damage in Patients with Newly Diagnosed Multiple Sclerosis: Contributions of the Soluble CD163 CSF/Serum Ratio to a Biomarker Panel , 2015, PloS one.

[15]  O. Ciccarelli,et al.  Exploring the origins of grey matter damage in multiple sclerosis , 2015, Nature Reviews Neuroscience.

[16]  H. Møller,et al.  Soluble CD163 as a Marker of Macrophage Activity in Newly Diagnosed Patients with Multiple Sclerosis , 2014, PloS one.

[17]  A. Huber,et al.  Type-I Interferons Suppress Microglial Production of the Lymphoid Chemokine, CXCL13 , 2014, Glia.

[18]  Richard Reynolds,et al.  Cortical grey matter demyelination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. , 2013, Brain : a journal of neurology.

[19]  M. Calabrese,et al.  Cortical lesion load associates with progression of disability in multiple sclerosis. , 2012, Brain : a journal of neurology.

[20]  David H. Miller,et al.  Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. , 2012, The New England journal of medicine.

[21]  Bruce Fischl,et al.  FreeSurfer , 2012, NeuroImage.

[22]  A. Bar-Or,et al.  Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro , 2012, Journal of Neuroimmunology.

[23]  B. Scheithauer,et al.  Inflammatory cortical demyelination in early multiple sclerosis. , 2011, The New England journal of medicine.

[24]  Bruce Fischl,et al.  Avoiding asymmetry-induced bias in longitudinal image processing , 2011, NeuroImage.

[25]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[26]  O. Ciccarelli,et al.  Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI , 2011, Neurology.

[27]  N. Esen,et al.  The lymphoid chemokine, CXCL13, is dispensable for the initial recruitment of B cells to the acutely inflamed central nervous system , 2010, Brain, Behavior, and Immunity.

[28]  R. Reynolds,et al.  A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis , 2010, Annals of neurology.

[29]  G. Comi,et al.  Freedom from disease activity in multiple sclerosis , 2010, Neurology.

[30]  J. Fleming,et al.  A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking , 2009, Neurology.

[31]  F. Barkhof,et al.  Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial , 2008, The Lancet Neurology.

[32]  Hans Lassmann,et al.  The Immunopathology of Multiple Sclerosis: An Overview , 2007, Brain pathology.

[33]  F. Aloisi,et al.  Lymphoid neogenesis in chronic inflammatory diseases , 2006, Nature Reviews Immunology.

[34]  Hans Lassmann,et al.  Cortical demyelination and diffuse white matter injury in multiple sclerosis. , 2005, Brain : a journal of neurology.

[35]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[36]  R. Reynolds,et al.  Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. , 2007, Brain : a journal of neurology.